| Literature DB >> 31125821 |
Wen-Jing Yi1, Yu-Shuai Han2, Li-Liang Wei3, Li-Ying Shi4, Huai Huang5, Ting-Ting Jiang6, Zhi-Bin Li7, Jing Chen8, Yu-Ting Hu9, Hui-Hui Tu10, Ji-Cheng Li11.
Abstract
Lack of laboratory standards for cured tuberculosis (TB) can lead to early discharge of untreated TB patients from the hospital, resulting in increased risk of TB spread and of developing drug resistant Mycobacterium tuberculosis (Mtb). We used ultra-high performance liquid chromatography coupled with mass spectrometry (LC-MS) to detect heparin anticoagulant in plasma of untreated TB patients, two-month treated TB patients, cured TB subjects, and healthy controls. Screening of differentially expressed metabolites resulted in identification of four differentially expressed metabolites such as, l-Histidine, Arachidonic acid (AA), Biliverdin, and l-Cysteine-glutathione disulfide after 6 months of TB treatment. Among them, l-Cysteine-glutathione disulfide and AA could be identified after 2 months of TB treatment. We established a cured TB model with an area under the curve (AUC) of 0.909 (95% CI, 0.802-0.970), 86.2% sensitivity, and 85.2% specificity. The diagnostic model fitted from the four differential metabolites in combination (l-Histidine, AA, Biliverdin, and l-Cysteine-glutathione disulfide) can be used as potential biomarkers for cured TB. Our study provided laboratory standards for hospital discharge of TB patients, as well as experimental basis for evaluating the efficacy of anti-TB drugs.Entities:
Keywords: Biomarkers; Metabolomics; Potential cure criteria; Tuberculosis
Mesh:
Substances:
Year: 2019 PMID: 31125821 DOI: 10.1016/j.biopha.2019.108980
Source DB: PubMed Journal: Biomed Pharmacother ISSN: 0753-3322 Impact factor: 6.529